Jean Paul Richter, writer ( )
|
|
- Angelina Bennett
- 5 years ago
- Views:
Transcription
1 The words a father speaks to his children in the privacy of the home are not overheard at the time, but, as in whispering galleries, they will be clearly heard at the end and by posterity. Jean Paul Richter, writer ( )
2 Disclosures Psychopharmacology and ASD Evdokia Anagnostou, MD Clinician Scientist, Bloorview Research Institute Associate Professor, Department of Pediatrics, University of Toronto Consulting: Roche Collaborations: SIEMENS Funding: Ontario Brain Institute, CIHR, DoD, HRSA, NCE- NeuroDevNet, Autism Speaks, PSI, ALVA foundation, Brain Canada Unrestricted grant: Sanofi-Aventis Grant support: SynapDx 1 2 Anxiety/ depression Affective lability Sensory-motor dysfunction Socialcommunication Deficits Repetitive behaviors / restricted interests ASD Impulsive aggression GI dysfunction, sleep dysfunction, ADHD like epilepsy Learning Attention Memory 3 4 Before we get started Principles of making a decision about starting medication ATN toolkits: Autism and Medication: Safe and careful Use: A guide for Families of Children with Autism Challenging Behaviors Toolkit Medication Decision aid toolkit What is the target symptom What are the side effects Other questions: feasibility based on frequency of dosing, requirements for blood work Who should know, who should monitor 5 6 1
3 Common target symptoms What we knowclinical trials in autism Aggression/ irritability, tantrums, self injury Hyperactivity, Inattention Repetitive behaviors Atypical neuroleptics (e.g. risperidone, aripiprazole) Aggression / Irritability Repetitive behaviors Attention / hyperactivity Sleep Anxiety Depression SSRIs, SNRIs (e.g. fluoxetine, sertraline, citalopram) --- Sleep issues Stimulants (e.g. methylphenidate, amphetamines) +++ α and β modulators (e.g. clonidine, guanfacine) Mood stabilizers (e.g. valproate ) ++(+) melatonin ++ (+) 7 8 Attention / Hyperactivity Clinical Practice Pathways for Evaluation and Medication Choice for Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum Disorders Methylphenidate Mahajan R, Bernal MP, Panzer R, Whitaker A, Roberts W, Handen B, Hardan A, Anagnostou E, Veenstra-VanderWeele J; Autism Speaks Autism Treatment Network Psychopharmacology Committee. Pediatrics Nov;130 Suppl 2:S doi: /peds J. Review
4 Cochrane Database Syst Rev Jan 24;(1): Risperidone for autism spectrum disorder. Jesner OS, Aref-Adib M, Coren E. ADHD like symptoms and autism 2 NE Receptor agonists: (e.g. Jaselskis et al., 1992) Clonidine: Open label and one placebo controlled studies Improvement in hyperactivity, irritability, stereotypies, global severity SE: hypotension, bradycardia, sedation Dosing: Clonidine dosage for ADHD in children is 5 micrograms per kilogram of body weight per day orally in four divided doses. Guanfacine: data moderately positive (Handen et al, 2008) Intuniv dosing: 1-4 mg qd Irritability/aggression Atypical Antipsychotics McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics May;127(5):e Evidence for effectiveness only in the case of risperidone and aripiprazole
5 Atypical Antipsychotics Cochrane Database Syst Rev Jan 24;(1): Risperidone for autism spectrum disorder. Jesner OS, Aref-Adib M, Coren E. The only drugs with FDA indication for use in children with ASD (risperidone and aripiprazole) Adverse events Pharmacogenetics of risperidone (Hoekstra et al 2010) In RUPP trials Increased appetite Fatigue Drowsiness Drooling Weight gain Other EPS, TD Prolongation of QT (very small effect) hyperprolactinemia In a 8 week open label study Carriers of the HTR2C promoter T allele gained an average of ± body mass indexstandardized z scores (1.84 ± 1.51 kg) versus 0.64 ± 0.35 z (3.23 ± 1.47 kg) for non-t-allele carriers (p < 0.001). Weight gain appeared to be associated with younger age and higher doses of risperidone Aripiprazole for autism spectrum disorders (ASD) Heidi Ching, Tamara Pringsheim Cochrane library, 16 MAY 2012 Forest plot of comparison: Aripiprazole vs. Placebo in Randomised Controlled Trials, outcome: ABC Irritability Subscale Mean Score Changes. Line-item analysis of the Aberrant Behaviour Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. (Aman et al 2010) Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the ABC-Irritability total subscale score and on the following individual ABC-Irritability items: Mood changes quickly, cries/screams inappropriately, stamps feet/bangs objects. Several additional items measuring tantrum-like behaviours improved in the flexibly dosed trial and at least one arm of the fixed-dose trial (p < 0.05). Measures of self-injurious behaviour, demonstrated numerical, but not statistically significant, improvement in both trials
6 1 year open label (continuation and novo) (Marcus et al 2011) Atypical Antipsychotics Drug Starting Dose Effective Dose Dosing Frequency Side-effect Consideration Monitoring Considerations Risperidone QDAY-TID Weight gain, EPS/TD Hyperprolactinemia Sedation Olanzapine QDAY-TID Weight gain, EPS/TD Hyperprolactinemia 1 Sedation Quetiapine QDAY-TID Weight gain, EPS/TD Hyperprolactinemia 1 Sedation Ziprasidone QDAY-TID Weight neutral?, EPS, QT prolongation Hyperprolactinemia Behavioral activation Aripiprazole QDAY-BID Not quite weight neutral EPS/TD Weight, BMI, Fasting glucose and lipid profile AIMS, Prolactin Weight, BMI, Fasting glucose and lipid profile, AIMS Weight, BMI, Fasting glucose & lipid profile, AIMS Weight, BMI, Fasting glucose and lipid profile AIMS, ECG Weight, BMI, Fasting glucose & lipids, AIMS 25 Modified from Posey et al Repetitive behaviors Thoughts about the construct OCD vs repetitive behaviors of autism Distressing vs pleasurable Distressing to whom? Not pediatrics, not ASD Citalopram, STAART King et al 2009 Cochrane Database Syst Rev Jan 24;(1): Risperidone for autism spectrum disorder. Jesner OS, Aref-Adib M, Coren E
7 Sleep BUT Risk to benefit ratio Dev Med Child Neurol Sep;53(9): Melatonin in autism spectrum disorders: a systematic review and metaanalysis. Rossignol DA, Frye RE Sleep Dev Med Child Neurol Sep;53(9): Melatonin in autism spectrum disorders: a systematic review and metaanalysis. Rossignol DA, Frye RE Unmed needs, no data Monitoring guidelines Anxiety (SSRIs, SNRIs, Buspirone) Depression (SSRIs, SSNRIs, Buproprion)
8 Use CDC calculator to calculate value 1 CAMESA guidelines Monitoring Safety of Second Generation Antipsychotics (SGA) in Children Patient Name: Gender: DOB (YYYY/M M/DD): SGA Medication: risperidone (Risperdal) Parameter Target Symptoms (e.g. tics, rage, psychosis): Pre-Treatment 1 Month 2 Month 3 Month 6 Month 9 Month 12 Month Baseline General Information: Assessment Date (YYYY/MM/DD): Patient Age at Assessment: Daily Dose of risperidone: mg mg mg mg mg mg mg Physical Examination Maneuvers: Height (cm) 1 Round to nearest 5, 10, 25, Height percentile 50, 75, 90, or 95 %ile Weight (kg) 1 Round to nearest 5, 10, 25, Weight percentile 50, 75, 90, or 95 %ile BMI (kg/m 2 ) 1 BMI percentile 1 Waist Circumference (at level of umbilicus) (cm) 2 >90, or round to nearest 10, Waist Circumference percentile 25, 50, 75, or 90 %ile Systolic Blood Pressure (mm Hg) 3 Provide range (<50, 50-90, Systolic Blood Pressure percentile 90-95, 95-99, or 99) Diastolic Blood Pressure (mm Hg) 3 Provide range (<50, 50-90, Diastolic Blood Pressure percentile 90-95, 95-99, or 99) Neurological Examination: Neurological Exam Normal or Abnormal? Laboratory Evaluations: #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Neurological Exam completed? 4 Test Normal Values ,8 5,7 Fasting Plasma Glucose 6.1 mmol/l 6, ,8 6, 7 Fasting Insulin 100 pmol/l 7, Fasting Total Cholesterol < 5.2 mmol/l 7, Fasting LDL-C < 3.35 mmol/l 7, Fasting HDL-C 1.05 mmol/l 7, Fasting Triglycerides < 1.5 mmol/l AST ALT , Prolactin Amylase Other (e.g. A1C, OGTT, etc.); Please List Physician Initials: Ameis SH, Corbett-Dick P, Cole L, Correll CU. Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: applying guidelines in the real world. J Clin Psychiatry Oct;74(10): Dosing Metformin (Riomet ) and matching placebo was donated by Ranbaxy Pharmaceuticals Inc. For children from 6-9 years of age: Started at 250 qhs, increased the 250 bid and then 500bid For children from years of age Same titration up to week 4, but then up to 850 bid
9 43 44 Adverse Events Days of gastrointestinal distress Abnormal feces Metformin (n = 28) Placebo (n = 32) Treatment Difference 16-week 16-week Effect 95% CI p 95% CI p 16-week change 95% CI Change Change Size p Total cholesterol (mmol/l) (-0.227,0.173) (-0.268,0.097) (-0.212,0.328) LDL (mmol/l) (-0.271,0.043) (-0.158,0.137) (-0.318,0.111) HDL (mmol/l) (-0.037,0.206) (-0.136,0.085) (-0.053,0.273) Triglycerides (mmol/l) (-0.252,0.382) (-0.222,0.361) (-0.418,0.408) Glucose, fasting (mmol/l) (-0.371,0.031) (-0.320,0.052) (-0.287,0.215) Insulin, fasting (pmol/l) 13.7 (-72.5,99.9) (-58.6,99.7) (-123.7,110.1) HOMA-IR 0.53 (-2.39,3.44) (-2.07,3.26) (-3.99,3.86) Hgb A1C (mmol/mol) (-1.56,0.39) (-0.51,1.25) (-2.26,0.35) ABC Lethargy (-4.80,0.63) (-3.64,1.52) (-4.54,2.50) ABC Stereotypy (-1.54,0.85) (-2.30,-0.03) (-0.72,2.36) ABC Hyperactivity (-3.79,1.50) (-4.10,0.89) (-3.09,4.00) ABC Inappropriate Speech (-1.37,0.03) (-0.77,0.55) (-1.50,0.38) From disability to possibility 47 8
10 Methylphenidate 10
11 11
12 12
13 Cochrane Database Syst Rev Jan 24;(1): Risperidone for autism spectrum disorder. Jesner OS, Aref-Adib M, Coren E. 13
14 15
15 16
16 Cochrane Database Syst Rev Jan 24;(1): Risperidone for autism spectrum disorder. Jesner OS, Aref-Adib M, Coren E. 20
17 Aripiprazole for autism spectrum disorders (ASD) Heidi Ching, Tamara Pringsheim Cochrane library, 16 MAY 2012 Forest plot of comparison: Aripiprazole vs. Placebo in Randomised Controlled Trials, outcome: ABC Irritability Subscale Mean Score Changes. 23
18 1 year open label (continuation and novo) (Marcus et al 2011) 25
19 Atypical Antipsychotics Drug Starting Dose Effective Dose Dosing Frequency Side-effect Consideration Monitoring Considerations Risperidone QDAY-TID Weight gain, EPS/TD Hyperprolactinemia Sedation Olanzapine QDAY-TID Weight gain, EPS/TD Hyperprolactinemia 1 Sedation Quetiapine QDAY-TID Weight gain, EPS/TD Hyperprolactinemia 1 Sedation Ziprasidone QDAY-TID Weight neutral?, EPS, QT prolongation Hyperprolactinemia Behavioral activation Aripiprazole QDAY-BID Not quite weight neutral EPS/TD Weight, BMI, Fasting glucose and lipid profile AIMS, Prolactin Weight, BMI, Fasting glucose and lipid profile, AIMS Weight, BMI, Fasting glucose & lipid profile, AIMS Weight, BMI, Fasting glucose and lipid profile AIMS, ECG Weight, BMI, Fasting glucose & lipids, AIMS Modified from Posey et al
20 Not pediatrics, not ASD 27
21 Citalopram, STAART King et al
22 Cochrane Database Syst Rev Jan 24;(1): Risperidone for autism spectrum disorder. Jesner OS, Aref-Adib M, Coren E. 30
23 Sleep Dev Med Child Neurol Sep;53(9): Melatonin in autism spectrum disorders: a systematic review and metaanalysis. Rossignol DA, Frye RE. 32
24 Sleep Dev Med Child Neurol Sep;53(9): Melatonin in autism spectrum disorders: a systematic review and metaanalysis. Rossignol DA, Frye RE. 33
25 CAMESA guidelines Monitoring Safety of Second Generation Antipsychotics (SGA) in Children Patient Name: Gender: DOB (YYYY/MM/DD): SGA Medication: risperidone (Risperdal) General Information: Parameter Physical Examination Maneuvers: Height (cm) Height percentile 1 Round to nearest 5, 10, 25, 50, 75, 90, or 95 %ile Weight (kg) Weight percentile 1 Round to nearest 5, 10, 25, 50, 75, 90, or 95 %ile BMI (kg/m 2 ) 1 BMI percentile 1 Use CDC calculator to calculate value 1 Waist Circumference (at level of umbilicus) (cm) Waist Circumference percentile 2 >90, or round to nearest 10, 25, 50, 75, or 90 %ile Systolic Blood Pressure (mm Hg) Systolic Blood Pressure percentile 3 Provide range (<50, 50-90, 90-95, 95-99, or 99) Diastolic Blood Pressure (mm Hg) Diastolic Blood Pressure percentile 3 Provide range (<50, 50-90, 90-95, 95-99, or 99) Neurological Examination: Neurological Exam completed? 4 Neurological Exam Normal or Abnormal? Laboratory Evaluations: Test Fasting Plasma Glucose 5 Fasting Insulin 6, 7 Fasting Total Cholesterol 7, 8 Fasting LDL-C 7, 8 Fasting HDL-C 7, 8 Fasting Triglycerides 7, 8 Normal Values 6.1 mmol/l 100 pmol/l < 5.2 mmol/l < 3.35 mmol/l 1.05 mmol/l < 1.5 mmol/l Target Symptoms (e.g. tics, rage, psychosis): mg mg mg mg mg mg mg 5 5 5,8 5, ,8 6, AST ALT , 10 Prolactin Amylase Other (e.g. A1C, OGTT, etc.); Please List Assessment Date (YYYY/MM/DD): Patient Age at Assessment: Daily Dose of risperidone: Physician Initials: Pre-Treatment Baseline #DIV/0! 1 Month #DIV/0! 2 Month #DIV/0! 3 Month #DIV/0! 6 Month #DIV/0! 9 Month 12 Month #DIV/0! #DIV/0! 37
26 38
27 41
28 43
29 44
30 Metformin (n = 28) Placebo (n = 32) Treatment Difference 16-week Change 95% CI p 16-week Change 95% CI p 16-week change 95% CI Effect Size p Total cholesterol (mmol/l) (-0.227,0.173) (-0.268,0.097) (-0.212,0.328) LDL (mmol/l) (-0.271,0.043) (-0.158,0.137) (-0.318,0.111) HDL (mmol/l) (-0.037,0.206) (-0.136,0.085) (-0.053,0.273) Triglycerides (mmol/l) (-0.252,0.382) (-0.222,0.361) (-0.418,0.408) Glucose, fasting (mmol/l) (-0.371,0.031) (-0.320,0.052) (-0.287,0.215) Insulin, fasting (pmol/l) 13.7 (-72.5,99.9) (-58.6,99.7) (-123.7,110.1) HOMA-IR 0.53 (-2.39,3.44) (-2.07,3.26) (-3.99,3.86) Hgb A1C (mmol/mol) (-1.56,0.39) (-0.51,1.25) (-2.26,0.35) ABC Lethargy (-4.80,0.63) (-3.64,1.52) (-4.54,2.50) ABC Stereotypy (-1.54,0.85) (-2.30,-0.03) (-0.72,2.36) ABC Hyperactivity (-3.79,1.50) (-4.10,0.89) (-3.09,4.00) ABC Inappropriate Speech (-1.37,0.03) (-0.77,0.55) (-1.50,0.38)
Complementary and alternative treatments
Complementary and alternative treatments Evdokia Anagnostou, MD Clinician Scientist, Bloorview Research Institute Associate Professor, Department of Pediatrics, University of Toronto Disclosures Consulting:
More informationMedications in Autism: What We Know and Don't Know
Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental
More informationAlpha-2 Agonists. Antipsychotics
Table 5: Randomized Controlled Trials of Psychotropic Medications in Children and Adolescents with ASD Agent Study Target Symptoms Dose Demographics Significant Side Clonidine Guanfacine Jaselskis et al.,
More informationSupplementary Online Content
Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationChallenging ASD Cases November 11, Melanie Penner, MD, MSc, Mohammad Zubairi, MD, MEd,
Challenging ASD Cases November 11, 2017 Melanie Penner, MD, MSc, FRCPC @drmelpenner Mohammad Zubairi, MD, MEd, FRCPC @md_mszubairi Learning Objectives By the end of this workshop, participants will: 1)
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder
Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More information3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM
Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive
More informationRole of ADHD medication in children with autism spectrum disorder. Pieter Hoekstra University of Groningen, Netherlands
Role of ADHD medication in children with autism spectrum disorder Pieter Hoekstra University of Groningen, Netherlands Symptoms of ADHD are highly prevalent in children with ASD Two independent chart reviews
More informationMedication management in children and youth with ASD
Medication management in children and youth with ASD Evdokia Anagnostou, MD Clinician Scientist, Bloorview Research Institute Assistant Professor, Department of Pediatrics University of Toronto Disclosures
More informationPsychopharmacology of Autism Spectrum Disorder
Psychopharmacology of Autism Spectrum Disorder Christopher J. McDougle, MD Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral Hospital
More information11/2/2016 INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM FACULTY DISCLOSURE
FACULTY DISCLOSURE INSIDE THE MIND OF A CHILD PSYCHIATRIST: PROBLEM BEHAVIORS IN CHILDREN WITH AUTISM KristinDawson, MD Assistant Professor University of Kentucky No commercial conflicts of Interest Salary
More informationDevelopmental Disorders
Pharmacology of Pervasive Developmental Disorders W. David Lohr, M.D. Assistant Professor Child Psychiatry Bingham Child Guidance Center University of Louisville School of Medicine 502-852-1065 wdlohr01@louisville.edu
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationDisclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013
A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote
More informationUsing Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University
Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal Alan Poling, Ph.D., BCBA-D Western Michigan University In a 2010 study of 60,641 children Mandell et al. found that: 56%
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationUpdate on clinical trials in ASD
Update on clinical trials in ASD Evdokia Anagnostou, MD Clinician Scientist, Bloorview Research Institute Assistant Professor, Department of Pediatrics University of Toronto Current approaches Medications
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationWhat About Health 3: Challenging Behaviors
The title of this presentation is What About Health. I m. In this presentation I will discuss a number of health and mental health issues related to children with ASD. 1 Now I am going to switch to discussing
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationTools that make a difference in mental health symptoms of autistic spectrum children Sumru Bilge-Johnson M.D. Program Director of Child Psychiatry
Tools that make a difference in mental health symptoms of autistic spectrum children Sumru Bilge-Johnson M.D. Program Director of Child Psychiatry Fellowship Associate Professor, Child Psychiatry NEOMED
More informationCardiometabolic Side Effects of Risperidone in Children with Autism
Cardiometabolic Side Effects of Risperidone in Children with Autism Susan J. Boorin, MSN, PMHNP-BC PhD Candidate Yale School of Nursing 1 This speaker has no conflicts of interest to disclose. 2 Boorin
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationTreatment of Autism Spectrum Disorder in Children and Adolescents
Evidence-Based Medicine Key Words: autism spectrum disorder, treatment, psychotherapy, psychopharmacology Treatment of Autism Spectrum Disorder in Children and Adolescents By Melissa DeFilippis, Karen
More informationDOI: /peds D. The online version of this article, along with updated information and services, is located on the World Wide Web at:
Use of Psychotropic Medication in Children and Adolescents With Autism Spectrum Disorders Daniel L. Coury, Evdokia Anagnostou, Patricia Manning-Courtney, Ann Reynolds, Lynn Cole, Robin McCoy, Agnes Whitaker
More informationPaediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK).
Paediatric Psychopharmacology. Dr Jalpa Bhuta. MD, DNB, MRCPsych (UK). Childhood pharmacokinetics Children have greater hepatic capacity More glomerular filtration Less fatty tissue Less ability to store
More informationBiomedical and Vocational Interventions for Adults with Autism
Biomedical and Vocational Interventions for Adults with Autism Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Integration of Adults with Autism into the Whole of Society People With
More informationAutism Spectrum Disorder and Mental Health Challenges in Youth
Autism Spectrum Disorder and Mental Health Challenges in Youth Management in the Primary Care Setting February 13, 2016 Rebecca Marshall, MD, MPH Outline DSM V Criteria Comorbidities Behavioral treatments
More informationDisclosures. Autism Society of Wisconsin. Case 2. Case 1. Case 3. Case 4 3/29/2018. Medication treatment for people with Autism Spectrum Disorder
Medication treatment for people with Autism Spectrum Disorder Autism Society of Wisconsin April 20, 2018 Richard P. Barthel, M.D. Disclosures In accordance with the ACCME policy on relevant financial disclosure,
More informationPsychopharmacology of Autism Spectrum Disorders
Psychopharmacology of Autism Spectrum Disorders Gabriel Kaplan, MD a,b, *, James T. McCracken, MD c KEYWORDS Autism spectrum disorders Autism Stimulants Irritability Repetitive behaviors Hyperactivity
More informationPsychotropics in Learning Disabilities: Systematic reviews. Professor Shoumitro Deb FRCPsych, MD University of Birmingham
Psychotropics in Learning Disabilities: Systematic reviews Professor Shoumitro Deb FRCPsych, MD University of Birmingham HTA EVIDENCE CATEGORIES Type I: RCTs/ Meta analysis Type II: Other controlled studies
More informationPharmacological management in children and adolescents with pervasive developmental disorder
Pharmacological management in children and adolescents with pervasive developmental disorder Min Sung, Daniel S. S. Fung, Yiming Cai, Yoon Phaik Ooi Objective: Pervasive developmental disorder (PDD) is
More informationAutism Spectrum Disorders & Attention Deficit Disorder in PEDIATRIC PRIMARY CARE. Disclosures
Autism Spectrum Disorders & Attention Deficit Disorder in PEDIATRIC PRIMARY CARE TIPS Conference March 22, 2019 Benjamin L. Handen, PhD, BCBA-D Professor of Psychiatry and Pediatrics Western Psychiatric
More informationAutism: Improving Health Care Outcomes
AUTISM AWARESS CONFERENCE Lewis County Autism Coalition 23 September 2011 Autism: Improving Health Care Outcomes Glenn C. Tripp, M.D. Developmental Behavioral Pediatrics Medical Director, Developmental
More informationAlgorithm for Management of Irritability in Children and Adolescents with ASD: Pharmacotherapy
Algorithm for Management of Irritability in Children and Adolescents with ASD: Pharmacotherapy Dr. Dean Elbe, PharmD, BCPP Clinical Pharmacy Specialist, Child & Adolescent Mental Health November 16, 2016
More informationPsychotropic Medications for Challenging Behaviors and Co-occurring Psychiatric Disorders In Autism. David Camenisch, MD/MPH
Psychotropic Medications for Challenging Behaviors and Co-occurring Psychiatric Disorders In Autism David Camenisch, MD/MPH Objectives Attendees will learn about the epidemiology of cooccurring psychiatric
More informationAggression (Severe) in Children under Age 6
Aggression (Severe) in Children under Age 6 Level 0 Comprehensive diagnostic assessments. Refer to Principles of Practice on page 6. Evaluate and treat comorbid conditions (i.e. medical, other psychiatric
More informationJennifer Zarcone. Kennedy Krieger Institute and Johns Hopkins School of Medicine
Jennifer Zarcone Kennedy Krieger Institute and Johns Hopkins School of Medicine 1 2 Estimated that between 20% to 45% of people with autism and ID are taking psychotropic medication 14% 30% are taking
More informationTics in the Pediatric Population: Pragmatic Management
CLINICAL PRACTICE Tics in the Pediatric Population: Pragmatic Management Christos Ganos, MD, 1,2 Davide Martino, MD, PhD, 3,4 Tamara Pringsheim, MD 5, * Abstract: Background: Primary tic disorders, notably
More informationMore than We Bargained For: Metabolic Side Effects of Antipsychotic Medications
More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received
More informationThe evidence for (or against) therapies in autism. With thanks to Danielle Wheeler and other systematic reviewers
The evidence for (or against) therapies in autism With thanks to Danielle Wheeler and other systematic reviewers Many different popular biomedical interventions Drug-based Complementary medicine Cochrane
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More information11/11/2018. The ABCs of Medication Management for Autism Spectrum Disorder. ABC Logging (FBA) First. ABC Logging HOW TO COMPLEMENT BEHAVIORAL THERAPY
The ABCs of Medication Management for Autism Spectrum Disorder OR HOW TO COMPLEMENT BEHAVIORAL THERAPY ABC Logging (FBA) First We need to know what, when, where and why behaviors happen. Antecedent: What
More informationAutism Spectrum Disorder: An Update Kathleen A. Koth, D.O.
Autism Spectrum Disorder: An Update Kathleen A. Koth, D.O. Assistant Professor, Child and Adolescent Psychiatry Program Director, Child and Adolescent Psychiatry Fellowship President, Wisconsin Council
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More information29 th Annual Learning Symposium
Friday, January 5, 9 Breakout Session 9 th Annual Learning Symposium ADHD & Medication Steven Pliszka, M.D. Dr. Steven Pliszka is a Dielmann Distinguished Professor and Chair of the Department of Psychiatry
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationObjectives. Disclosure of Commercial Support. Psychopharmacology and Pediatric Obesity
Psychopharmacology and Pediatric Obesity Raise awareness of the complex interplay between mental illness and obesity/metabolic disturbances in children Dina Panagiotopoulos, MD, FRCPC Clinical Professor
More informationPromoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives
Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy
More informationEvidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center
Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationADHD in the Preschool Aged Child
ADHD in the Preschool Aged Child (PATS) 11/2/2013 Stephen Meister MD, MHA, FAAP The Edmund N Ervin Pediatric Center (PATS) National Institute of Mental Health study First papers published in 2006 after
More informationAutism/Pervasive Developmental Disorders Update. Kimberly Macferran, MD Pediatric Subspecialty for the Primary Care Provider December 2, 2011
Autism/Pervasive Developmental Disorders Update Kimberly Macferran, MD Pediatric Subspecialty for the Primary Care Provider December 2, 2011 Overview Diagnostic criteria for autism spectrum disorders Screening/referral
More informationASD (hyperactivity) 3 rd LINE TREATMENT Initial liquid dose mg 2. - ADHD symptoms without sleep
Generic Name Label Name Dosing by Disorder RITALIN, RITALIN LA, CONCERTA, METADATE ER, 2 ND LINE TREATMENT 2 ND LINE TREATMENT METADATE CD, MPH ER, Initial liquid dose 1-5 mg 1,2 Initial liquid dose 1-5mg
More informationBob Klaehn, M.D. Bob Klaehn, M.D. October 3, /30/14
Bob Klaehn, M.D. October 3, 2014 1 Bob Klaehn, M.D. Medical Director, Arizona Division of Developmental Disabilities since 2001 Faculty, MIHS Child Psychiatry Residency Program Child Psychiatrist, District
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationRisperidone use in children with autism carries heavy risks
NEWS Risperidone use in children with autism carries heavy risks BY EMILY ANTHES 28 APRIL 2014 1 / 6 Double edge: Risperidone can calm tantrums and aggression in some children with autism, but sleepiness
More informationReview family/child history of heart condition* interventions 1
ADHD Psychotherapeutic Trial Methylphenidate/Dexmethylphenidate Parent Behavior Medication can be discontinued quickly Training (PBT) Review family/child history of heart condition* interventions 1 1 /Screening
More informationEARLY ONSET SCHIZOPHRENIA
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington
More informationPediatrics Grand Rounds 9 April University of Texas Health Science Center at San Antonio. Overview. Prevalence of ASD (Cont.) Prevalence of ASD
9 April 200 Overview Diagnosis and Treatment of Autism Spectrum Disorders Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The
More informationADHD Explanation 5: Medications used in ADHD
ADHD Explanation 5: Medications The aim of treatment is efficient functioning and achieving goals in life It is most important to find the dose of medications that works best As children grow they may
More informationPsychiatric Disorders in Children and Adolescents D R P E Y M A N B A K H T I A R I A N C H I L D P S Y C H I A T R I S T M A Y 1 4 TH
Psychiatric Disorders in Children and Adolescents D R P E Y M A N B A K H T I A R I A N C H I L D P S Y C H I A T R I S T M A Y 1 4 TH 2 0 1 6 OUTLINE INTRODUCTION ANXIETY DISORDERS MOOD DISORDERS Depressive
More informationAttention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D.
ADHD in Preschool Children Preschool ADHD: When Should We Diagnose it & How Should We Treat it? Professor of Pediatrics Diagnosis of ADHD in Preschool Children: Impact of DSM-IV Is Preschool ADHD Associated
More informationEffective Health Care Program
Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the
More informationAtomoxetine. Open study showed 60% response of inattention and hyperactivity with a few much worse (Jou et al 2005)
Atomoxetine Open study showed 60% response of inattention and hyperactivity with a few much worse (Jou et al 2005) Buspirone Case reports (McCormick 1997, Hillbrand and Scott 1995,Realmuto et al 1989,
More informationA Rational Approach to Behavior Management & Psychopharmacology in Children with Developmental Disabilities
A Rational Approach to Behavior Management & Psychopharmacology in Children with Developmental Disabilities James Coplan, MD Neurodevelopmental Pediatrics of the Main Line Rosemont, PA info@drcoplan.com
More informationPrescribing antipsychotics for children and adolescents
POMH-UK Topic 10a baseline report Prescribing antipsychotics for children and adolescents September 2010 Prepared by the Prescribing Observatory for Mental Health-UK for Coventry and Warwickshire Partnership
More information10/3/2016. Disclaimer. What is Autism? Autistic Behaviors
A novel evidence based ranking scale for medications and supplements in autism spectrum disorders Dan Rossignol MD FAAFP Rossignol Medical Center Florida Office (Melbourne, FL): 321.259.7111 California
More informationMedication Management in Tic Disorders. Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18
Medication Management in Tic Disorders Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18 Speaker Disclosures: No relevant disclosures (Clinical research study funded in part
More informationADHD Part II: Managing Comorbities
ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationThe Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD
The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD Damon Korb, MD Behavioral and Developmental Pediatrician Director of the Center for Developing Minds Los Gatos,
More informationIntroduction. Objectives. Psychotropic Medications & Cardiometabolic Risk
Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More information10/7/16 ADHD: ASSESSMENT. Pharmacological Target Symptoms in Autism Spectrum Disorder (ASD) 1: REVIEW RATING SCALES AND RECORDS
Pharmacological Management of Autism Spectrum Disorder and ADHD: Help Group Summit 2016 Michael Enenbach, MD Associate Clinical Professor UCLA Department of Psychiatry Pharmacological Target Symptoms in
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 2: Antipsychotics & Mood Stabilizers Dr. Ajit Ninan & Joel Lamoure 1 : Who are we?
More informationUniversity of Texas Health Science Center at San Antonio. Pediatrics Grand Rounds 5 February History of stimulant treatment
Pharmacological Treatment of Attention Deficit Hyperactivity Disorder and its comorbidities Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department
More informationBehavior Management & Psychopharmacology James Coplan, MD, Session Page 1. Disclosures. Behavior. Internalizing Behavior.
Session Number: 5528 Behavior management and psychopharmacology in children with autistic spectrum disorders James Coplan, MD Neurodevelopmental Pediatrics of the Main Line Rosemont, PA info@drcoplan.com
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationAn Overview on the Use of Psychotropic Medications
An Overview on the Use of Psychotropic Medications Marilyn B. Benoit, M.D. Chief Clinical Officer SVP, Clinical & Professional Affairs Classes of Medications Antidepressants Anti-anxiety Mood stabilizers
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationABC Conference November 16, Behavior Management & Psychopharmacology James Coplan, MD. Page 3. Behavior.
Behavior management and psychopharmacology in children with autistic spectrum disorders James Coplan, MD Neurodevelopmental Pediatrics of the Main Line Rosemont, PA (610) 520-2130 11/16/2012 Learning Objectives
More informationManaging maladaptive behaviors in fragile X patients. Psychotropics can improve hyperactivity, anxiety, and aggression. For personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Managing maladaptive behaviors in fragile X patients Psychotropics can improve hyperactivity, anxiety, and aggression
More informationMedications in the School Setting. Kristen Nichols, PharmD, BCPS-AQ ID Butler University Riley Hospital for Children
Medications in the School Setting Kristen Nichols, PharmD, BCPS-AQ ID Butler University Riley Hospital for Children OBJECTIVES Discuss treatment options for treatment of attention-deficit/hyperactivity
More information